Article

FDA Briefs - March 1, 2002

Allergan's brimonidine tartrate (Alphagan) will have new labeling that indicates its 0.5% strength is suitable for pediatric patients over 2 years old.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
J. Peter Campbell, MD, MPH
Related Content
iVeena submits IND to FDA for phase 2 clinical trial for pediatric myopia
June 4th 2025

iVeena submits IND to FDA for phase 2 clinical trial for pediatric myopia

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Ocugen’s OCU410ST receives rare pediatric disease designation for the treatment of ABCA4-associated retinopathies
May 27th 2025

Ocugen’s OCU410ST receives rare pediatric disease designation for the treatment of ABCA4-associated retinopathies

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

FDA clears expansion of amblyopia treatment from Luminopia to include patients aged 8 to 12 years
May 1st 2025

FDA clears expansion of amblyopia treatment from Luminopia to include patients aged 8 to 12 years

Red light therapy in children with myopia
April 27th 2025

Red light therapy in children with myopia

© 2025 MJH Life Sciences

All rights reserved.